Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in ne...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Manasanch, Elisabet E., de Larrea, Carlos Fernández, Zingone, Adriana, Steinberg, Seth M., Kwok, Mary, Tageja, Nishant, Bhutani, Manisha, Kazandjian, Dickran, Roschewski, Mark, Wu, Peter, Carter, George, Zuchlinski, Diamond, Mulquin, Marcia, Lamping, Liz, Costello, Rene, Burton, Deborah, Gil, Lindsay A., Figg, William D., Maric, Irina, Calvo, Katherine R., Yuan, Constance, Stetler-Stevenson, Maryalice, Korde, Neha, Landgren, Ola
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6357961/
https://ncbi.nlm.nih.gov/pubmed/27687480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1214953
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados